Published On: 12/4/2024
The Liver Meeting 2024 Research: Presentation by A. Sidney Barritt IV, MD, MSCR
Lead author and member of the TARGET-NASH steering committee, A. Sidney Barritt IV, MD, MSCR, presented a new Target RWE study at The Liver Meeting 2024 titled, “Use of glucagon-like peptide 1 receptor agonists in patients with MASLD in a real-world setting is associated with slower disease progression and lower all-cause mortality.”
The study analyzed data from a real-world cohort of MASLD patients and found that those taking GLP-1 RAs had a significantly lower risk of death and progression to a more severe form of liver disease compared to non-users. Learn more about the impact of GLP-1 RAs on MASLD patient outcomes in this insightful presentation by Dr. Barritt.
About Target RWE
Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy.
Visit our website to learn more: https://targetrwe.com/
Contact:
Kayla Slake
Senior Manager, Marketing
984.234.0268 ext 205
More News
-
03/31/2025
Addressing the Burden of Hidradenitis Suppurativa: The Often-Hidden Impact on Quality of Life -
03/18/2025
AASLD Opens Call for Applications for Sites to Participate in TARGET-LD and the Cirrhosis Quality Collaborative (CQC Data Registry) -
03/07/2025
Patient-Centric Data Capture Fuels Growth of Target RWE Longitudinal, Real-World Dermatology Studies -
02/20/2025
Causal Inference for Regulatory-Grade Evidence Generation: Behind the Data -
01/31/2025
Maximizing the Value of Real-World Data: The Critical Role of Causal Inference in Pharmaceutical Innovation